Neurodegenerative diseases are one of the largest medical challenges of our time. Denali Therapeutics is a biotechnology company based in South San Francisco, California that is dedicated to defeating neurodegenerative diseases through rigorous therapeutic discovery and development. Denali is founded on the collaboration of leading scientists, industry experts, and investors who share the vision that scientific discovery energetically applied to translational medicine is the key to delivering effective therapies to patients.
The Opportunity
We are currently seeking an outstanding Associate Scientist to join our Preclinical Translational Sciences group. The primary function of this group is to leverage the use of animal models for biomarker discovery as well as establishing PK/PD relationships with Denali’s therapeutic candidates. The role will be critical in supporting the execution of all in vivo study activities.
Responsibilities (included but not limited to the following):
Requirements
Denali is committed to its core company value of Unity by creating a diverse and inclusive environment. We are proud to be an equal opportunity employer and do not discriminate against any employee or applicant for employment because of race, color, sex, age, national origin, religion, sexual orientation, gender identity and/or expression, status as a veteran, basis of disability, or any other federal, state, or local protected class.
Salary Range: $100,000 to $126,667. Compensation for the role will depend on a number of factors, including a candidate’s qualifications, skills, competencies, and experience. Denali offers a competitive total rewards package, which includes a 401k, healthcare coverage, ESPP and a broad range of other benefits. Learn more at https://www.denalitherapeutics.com/careers
*This compensation and benefits information is based on Denali’s good faith estimate as of the date of publication and may be modified in the future.
Applicant Privacy Policy
https://www.denalitherapeutics.com/denali-applicant-privacy-policy
#LI-SC1